Acasti Pharma, an emerging biopharmaceutical company, agreed to acquire Grace Therapeutics, a pharmaceutical company that focuses on drug delivery treatment for rare and orphan diseases, for c. $64m. “We have diligently pursued a thorough strategic process to evaluate a range of value-creating alternatives. We believe that combining Grace’s innovative research programs and scientific talent with Acasti’s financial resources and drug development and commercialization expertise position us to build a portfolio of innovative therapeutics that will address unmet medical needs. The Acasti and Grace boards have approved this transaction, which is also supported by Grace shareholders, and we highly recommend that our shareholders also approve it," Roddy Carter, Acasti Chairman.